News

The trial observations included an approximate 40% reduction in mortality for adenocarcinoma patients receiving Tavocept. The percentage of adenocarcinoma patients in the Tavocept group who were alive after

The global trials will compare the efficacy, safety and tolerability of TMC278 (25mg) once daily oral tablet versus efavirenz (EFV), each co-administered with a background regimen of two

The contract amount includes $170,000 payable under a letter of intent that was announced previously. The current trial will assess the efficacy and safety of multiple doses of

New investors Legg Mason Capital Management, GE Asset Management and Smallcap World Fund joined current investors Flagship Ventures, Gilde Healthcare Partners, Humana, and Stelios Papadopoulos in the round.

Asubio’s Biopten is said to be a highly pure chemically synthesized form of the tetrahydrobiopterin (BH4) that occurs naturally in the human body. It treats hyperphenylalaninemia (HPA) patients

This will result in the Bellus Health Group owning 100% of the capital stock, thereby acquiring all of the business of Innodia including the intellectual property assets related

Premier will focus on corporate imaging and creating retail market awareness for the existing and new shareholder base. Jing Wang, CEO and president of Huifeng, said: “We believe

The agreement provides Intermedica with the rights to sell in Russia, Belarussia, Kazakstan and the Ukraine, and includes minimum purchase requirements. The Sonablate SB500, a high intensity focused

Mr Merselis will also serve as a member of the company’s board of directors. Most recently, Mr Merselis served as president and CEO of HemoSense, a point-of-care diagnostics